Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

Arthritis Research & Therapy
Juan J Gomez-ReinoBIOBADASER Group

Abstract

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard...Continue Reading

References

Apr 1, 1992·British Journal of Rheumatology·M J WijnandsP L van Riel
Mar 1, 1992·Annals of the Rheumatic Diseases·H A Capell, M Brzeski
Apr 1, 1991·Statistics in Medicine·H Petri, J Urquhart
Nov 1, 1995·Annals of the Rheumatic Diseases·J De La MataJ J Gómez-Reino
Nov 1, 1995·Baillière's Clinical Rheumatology·F Wolfe
Apr 19, 2002·The Journal of Pharmacology and Experimental Therapeutics·Bernie ScallonCarrie Wagner
Aug 15, 2002·Annals of the Rheumatic Diseases·P GeborekUNKNOWN South Swedish Arthritis Treatment Group
Nov 19, 2002·Current Opinion in Pediatrics·Randy Q Cron
Dec 1, 1964·Postgraduate Medical Journal·J T PARK
Apr 3, 2004·Arthritis Research & Therapy·Eswar Krishnan, James F Fries
Apr 13, 2004·Arthritis and Rheumatism·Ennio Giulio FavalliIrene Pontikaki
May 14, 2004·Annals of the Rheumatic Diseases·F C Breedveld, J R Kalden
Jun 24, 2004·Expert Opinion on Pharmacotherapy·Daniel Wendling, Eric Toussirot
Jul 2, 2004·Arthritis Research & Therapy·Sergio Schwartzman, G James Morgan
Jul 2, 2004·Arthritis Research & Therapy·Alice B Gottlieb, Christian E Antoni
Feb 12, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·A E MoustouI Danopoulou
Apr 13, 2010·Clinical Rheumatology·Eduardo Nicolas PollonoMaria E Suarez-Almazor

❮ Previous
Next ❯

Citations

Jun 20, 2007·Annals of the Rheumatic Diseases·Ronald F van Vollenhoven
Jul 25, 2009·BMC Musculoskeletal Disorders·Federico Navarro-SarabiaJuan J Gómez-Reino
Apr 25, 2009·Arthritis Research & Therapy·Andrea Rubbert-Roth, Axel Finckh
Aug 1, 2012·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Janet PopeJohn Sampalis
Jan 1, 2010·Drug, Healthcare and Patient Safety·Ismail Simsek, Yusuf Yazici
Mar 25, 2008·Therapeutics and Clinical Risk Management·Philip Mease
Mar 29, 2014·Pharmacogenetics and Genomics·Ariana MontesAntonio Gonzalez
Nov 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Christine BeetonK George Chandy
Oct 5, 2007·Current Rheumatology Reports·Alan R Erickson, Ted R Mikuls
Apr 17, 2008·Clinical Rheumatology·Karin LaasMarjatta Leirisalo-Repo
Aug 12, 2008·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Ana M BertoliAlberto M Strusberg
Jun 6, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Laura J Gibbons, Kimme L Hyrich
May 28, 2008·Rheumatology International·C DuftnerM Herold
Apr 15, 2009·Current Opinion in Rheumatology·Toru Mima, Norihiro Nishimoto
May 2, 2009·Inflammatory Bowel Diseases·Leonidas A Bourikas, Konstantinos A Papadakis
Jul 16, 2010·Wiener medizinische Wochenschrift·Christoph StrehblowPeter Fasching
Aug 8, 2009·American Journal of Clinical Dermatology·Annamaria MazzottaSergio Chimenti
Dec 17, 2009·Ocular Immunology and Inflammation·Srilakshmi M SharmaAndrew D Dick
Feb 3, 2012·Immunopharmacology and Immunotoxicology·Giampiero GirolomoniGino Antonio Vena

❮ Previous
Next ❯

Software Mentioned

BIOBADASER

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.